Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE ...Middle East

SYDNEY, April 19, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has entered into a worldwide exclusive licensing agreement and a master services agreement with Evotec SE (FRA: EVT), a...

Hence then, the article about kazia licenses global rights to evt801 a novel first in class clinic ready vegfr3 inhibitor from evotec se was published today ( Monday 19/04/2021 - 12:46 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE )

Also on site :

• US wants Iran to pledge to stop shooting at ships in Strait of Hormuz
• Meta Removes Muse Image AI Feature After Backlash: “Missed The Mark”
• Morgan Spector In Talks To Play Robert Langdon, Rebecca Hall Eyed As Female Lead In Netflix Series Based On Dan Brown’s ‘The Secret of Secrets’